Part 3/7:
Understanding the Decision: Risk vs. Reward
While three years and $33 million may not seem unreasonable for a high-end reliever, the Phillies might have assessed other aspects of Hoffman's physical health as a decisive factor in their decision. Thomas speculates that the front office may have questioned Hoffman's longevity and overall performance consistency, leading them to seek alternatives that posed less risk.
The decision to not re-sign Hoffman, while potentially disappointing for fans, could ultimately prove to be prudent, considering the possibility of spending a similar amount on a healthy pitcher with fewer concerns.
Arbitration Insights: The Phillies’ Strategic Moves